Manuel A. Cobo-Dols - Publications

Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial.

Journal: The Lancet. Oncology

Published: March 20, 2026

Comparative effectiveness of two alternative dosing strategies of pembrolizumab in metastatic non-small-cell lung cancer in a real-world setting.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: November 06, 2025

Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 09, 2025

COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib.

Journal: ESMO open

Published: August 04, 2025

Multidisciplinary approach for patients with early and locally advanced non-small cell lung cancer (NSCLC): 2nd Spanish Lung Cancer Group (GECP) expert consensus statement.

Journal: Translational lung cancer research

Published: May 24, 2025

Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: August 21, 2024

Oncogene-addicted solid tumors and microbiome-lung cancer as a main character: a narrative review.

Journal: Translational lung cancer research

Published: March 06, 2024

Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: October 26, 2023

Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: September 05, 2023

Fluorometric Quantification of Total Cell-Free DNA as a Prognostic Biomarker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Blockade.

Journal: Cancers

Published: May 30, 2023

Synergy between imputed genetic pathway and clinical information for predicting recurrence in early stage non-small cell lung cancer.

Journal: Journal of biomedical informatics

Published: December 15, 2022

Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC.

Journal: JTO clinical and research reports

Published: October 26, 2022